Project Grant R43CA310649
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $406K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Cancer Institute awarded Embiosys Inc. $2,758,884 on September 17, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a wearable induced electric field therapy device for triple-negative breast cancer combined with capecitabine chemotherapy. Embiosys is developing a novel wearable garment (camisole/tank-top) that delivers induced electric field (IEF) therapy—a non-ionizing electromagnetic treatment targeting cancer cells with metastatic potential. Preclinical...
- The National Cancer Institute awarded the University of Virginia $404,349 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on April 1, 2026, to develop and validate quantitative magnetic resonance imaging methods for measuring macromolecular delivery to brain tumors following focused ultrasound and microbubble treatment. The research addresses the blood-tumor barrier, which limits therapeutic drug delivery to brain metastases and contributes to higher patient mortality...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded Vortex Therapeutics Inc. $3.347 million on September 12, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule MYC inhibitors for cancer therapy. The recipient is developing direct small-molecule inhibitors targeting MYC proteins (C-MYC, N-MYC, and L-MYC), which are oncogenic drivers implicated in at least 70 percent of all human cancers and are particularly...
- The National Cancer Institute awarded Nanocan Therapeutics Corporation $2,996,343 on September 24, 2025, to conduct the first clinical trial of the Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel for treatment of advanced cervical cancer under the Cancer Treatment Research program (CFDA 93.395). The LIFE gel is a biocompatible, biodegradable immunotherapeutic administered locally in conjunction with hypo-fractionated radiotherapy. The technology extends local radiotherapy's use from...
- The National Institutes of Health National Cancer Institute awarded Molecular Theranostics LLC $528,259 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop next-generation targeted MRI contrast agents for cancer detection and diagnosis. The recipient will design, synthesize, and optimize targeted gadolinium- and manganese-based MRI contrast agents using PYCLEN chelating ligands. The work addresses safety concerns associated with current...
- The National Cancer Institute awarded the University of California, Los Angeles $640,956 on May 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an artificial intelligence-enhanced perfusion MRI imaging biomarker for predicting yttrium-90 microsphere distribution in radioembolization treatment of liver cancer. The project addresses the current limitation that determining how Y90 microspheres disperse in a tumor relies on labor-intensive tracking of...
- The National Cancer Institute awarded the University of California, Davis $409,141 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop contrast-enhanced perfusion CT imaging as an alternative to current liver radioembolization workup procedures. The project addresses imaging optimization for selective internal radiation therapy (SIRT), a catheter-based treatment for liver cancer using radioactive yttrium-90 microspheres. Current clinical practice...
- This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...
- The National Cancer Institute awarded $1,008,660 to Aim Medical Robotics Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a commercial-grade MRI-compatible neurosurgical robotic system for minimally invasive laser interstitial thermal therapy (LITT) treatment of brain tumors. Aim Medical Robotics is refining and validating the AIM Robotic System, a compact robotic platform designed to complete the full LITT workflow...
- This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...